“Assuming the agency really did hard validate the self-scores of all proposals that advanced to phase 2, it appears unlikely that corrective action will displace any of the current ‘apparent successful offerors,’” the authors wrote. “The stay of award/performance, however, presumably will remain in place and prevent any task order competitions from proceeding under CIO-SP4 until the agency completes this latest round of corrective action.”
Source: Revalidation Unlikely to End NIH Tech-Deal Bid Protest Saga, By Jim Tucker and Damien Specht. Law360.